# Boris Duchemann

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/boris-duchemann/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,435 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 31 |
| i10-index | 63 |
| Last Known Institution | Université Paris-Saclay |
| OpenAlex ID | https://openalex.org/A5062179226 |
| ORCID iD | 0000-0003-0872-2983 |
| Works | 249 |

## Researcher papers

- [Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia](https://scholariq.org/papers/effect-of-tocilizumab-vs-usual-care-in-adults-hospitalized-with-covid-19-and/)
- [Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy](https://scholariq.org/papers/hyperprogressive-disease-in-patients-with-advanced-non-small-cell-lung-cancer/)
- [Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1](https://scholariq.org/papers/proteomic-profiling-identifies-dysregulated-pathways-in-small-cell-lung-cancer/)
- [Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris](https://scholariq.org/papers/prevalence-and-incidence-of-interstitial-lung-diseases-in-a-multi-ethnic-county/)
- [Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial](https://scholariq.org/papers/effect-of-anakinra-versus-usual-care-in-adults-in-hospital-with-covid-19-and/)
- [Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors](https://scholariq.org/papers/outcome-of-patients-with-non-small-cell-lung-cancer-and-brain-metastases-treated/)
- [Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST](https://scholariq.org/papers/monitoring-anti-pd-1-based-immunotherapy-in-non-small-cell-lung-cancer-with-fdg/)
- [Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy](https://scholariq.org/papers/circulating-t-cell-immunosenescence-in-patients-with-advanced-non-small-cell/)
- [Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?](https://scholariq.org/papers/why-does-circadian-timing-of-administration-matter-for-immune-checkpoint/)
- [Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials](https://scholariq.org/papers/anti-pd-l-1-for-kras-mutant-advanced-non-small-cell-lung-cancers-a-meta-analysis/)
- [Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study](https://scholariq.org/papers/histomolecular-resistance-mechanisms-to-first-line-osimertinib-in-egfr-mutated/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Université Paris-Saclay](https://scholariq.org/institutions/universite-paris-saclay/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.